NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
- PMID: 9878117
- DOI: 10.1006/cimm.1998.1396
NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies
Abstract
The 4-1BB (CDw137) T-cell molecule is a member of the TNF receptor family and triggering by either 4-1BB ligand or antibody ligation induces T-cell activation and growth. We have recently demonstrated that administration of anti-4-1BB monoclonal antibodies (mAb) induced the regression of established large tumors in several mouse models by activation of T-cell-mediated immunity. Herein we report that selective depletion of natural killer (NK) cells in mice by the anti-AsialoGM1 or anti-NK1.1 antibodies completely abrogated the antitumor effect of anti-4-1BB mAb. However, it is unlikely that NK1. 1 cells are the effectors of the response because P815 cells are resistant to lysis by NK1.1 cells in vitro. Despite the fact that activated NK1.1 cells express 4-1BB on their surface, redirection of NK1.1 cells by anti-4-1BB mAb or by transfection into P815 cells of the 4-1BB natural ligand did not trigger cytolysis. Our results thus gain further insight into the cellular mechanisms of the antitumor effects of anti-4-1BB mAb and implicate an immunoregulatory rather than effector function of 4-1BB molecule on NK1.1 cells.
Copyright 1998 Academic Press.
Similar articles
-
Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.Cancer Res. 2001 Mar 1;61(5):2031-7. Cancer Res. 2001. PMID: 11280763
-
Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.Cancer Res. 2002 Jun 15;62(12):3459-65. Cancer Res. 2002. PMID: 12067989
-
Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.Cancer Res. 2004 Nov 15;64(22):8411-9. doi: 10.1158/0008-5472.CAN-04-0590. Cancer Res. 2004. PMID: 15548712
-
Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.Arch Immunol Ther Exp (Warsz). 1999;47(5):275-9. Arch Immunol Ther Exp (Warsz). 1999. PMID: 10604232 Review.
-
Role of 4-1BB in immune responses.Semin Immunol. 1998 Dec;10(6):481-9. doi: 10.1006/smim.1998.0157. Semin Immunol. 1998. PMID: 9826581 Review.
Cited by
-
Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting.Oncoimmunology. 2021 Feb 4;10(1):1877459. doi: 10.1080/2162402X.2021.1877459. Oncoimmunology. 2021. PMID: 33643694 Free PMC article.
-
Harnessing NK Cell Checkpoint-Modulating Immunotherapies.Cancers (Basel). 2020 Jul 6;12(7):1807. doi: 10.3390/cancers12071807. Cancers (Basel). 2020. PMID: 32640575 Free PMC article. Review.
-
CD137 deficiency does not affect development of airway inflammation or respiratory tolerance induction in murine models.Clin Exp Immunol. 2012 Jun;168(3):308-17. doi: 10.1111/j.1365-2249.2012.04572.x. Clin Exp Immunol. 2012. PMID: 22519594 Free PMC article.
-
CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.J Clin Invest. 2003 May;111(10):1505-18. doi: 10.1172/JCI17662. J Clin Invest. 2003. PMID: 12750400 Free PMC article.
-
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.J Immunother Cancer. 2022 Mar;10(3):e003532. doi: 10.1136/jitc-2021-003532. J Immunother Cancer. 2022. PMID: 35236742 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials